Medivir AB Namn-Aktier o.N.

Sector and Industry

Healthcare, Biopharmaceuticals

Performance (1Y)

10.86%

Market Cap

-

P/E Ratio

0.00

Dividend Yield

0.00 %

Earnings per Share

-0.06 €

Peer Group

Company NameMarket CapRevenue Last Reported YearP/E RatioProfit Growth 1YLast PricePrevious Trading Day Change
Eli Lilly and Company864.54 Bil.57.78 Bil.46.82
+86.88 %
0.00
-
Johnson & Johnson425.70 Bil.83.48 Bil.18.82
+82.71 %
0.00
-
AbbVie Inc.343.94 Bil.54.21 Bil.96.78
-5.29 %
0.00
-
Roche Holding AG286.62 Bil.65.80 Bil.20.72
+58.45 %
0.00
-
AstraZeneca PLC244.91 Bil.52.09 Bil.27.55
+39.41 %
0.00
-
NOVARTIS AG 224.76 Bil.48.44 Bil.18.30
+12.45 %
0.00
-
Merck & Co. Inc.221.79 Bil.57.55 Bil.14.46
+2.25 %
0.00
-
Novo-Nordisk AS B193.52 Bil.41.49 Bil.14.11
+1.54 %
0.00
-
Amgen Inc.150.16 Bil.32.57 Bil.23.01
+80.77 %
0.00
-
Gilead Sciences Inc.129.70 Bil.26.10 Bil.18.10
+1,599.93 %
0.00
-

Facts & figures

Price data

TRADE PLATFORMBörse Stuttgart (XSTU)
LAST PRICE0.1446 G0 Units
PRICE DETERMINATION TIME07/24/2026 / 11:33:01 AM
DAILY VOLUME (UNITS)0
DAILY HIGH / LOW0.14540.1442
PREV. DAY'S PRICE0.1444 (07/23)
CHANGE DAY BEFORE
+0.00
0.14 %
52 WEEK HIGH / LOW0.258 (03/16)0.0001 (01/13)
More Price Information

Key Figures (in EUR)

2023202420252026e2027e
EARNINGS PER SHARE
-0.13-0.09-0.06-0.01-0.02
DIVIDENDS PER SHARE
0.000.000.000.000.00
DIVIDEND YIELD IN %
0.00 %0.00 %0.00 %--
DIVIDEND GROWTH IN %
-----
PRICE - EARNINGS RATIO
-----
PRICE - BOOK RATIO
1.372.761.18--
PRICE - SALES RATIO
22.5692.946.86--
PRICE - CASH FLOW RATIO
-----
Further Key Figures

Master Data

WKN
A3EFZT
ISIN
SE0020181014
SYMBOL
MVR0
EXCHANGE SEGMENT
Freiverkehr
TYPE OF FINANCIAL INSTRUMENT
Equity
DENOMINATION
MEDIVIR AB
INDEX MEMBERSHIP
-
TRADING SEGMENT
-
TRADING HOURS
07:30:00 AM - 10:00:00 PM
TRADING CURRENCY
Euro
NOMINAL CURRENCY
-
SETTLEMENT CURRENCY
Euro
SECTOR AND INDUSTRYHealthcare, Biopharmaceuticals
NUMBER OF SHARES
-
MARKET CAPITALISATION
-

Performance overview

1W1M3M6M1Y3Y5YYTD
PERFORMANCE
-3.22 %
2.70 %
-6.23 %
434.81 %
-10.86 %
-69.98 %
-79.99 %
344.31 %
HIGH0.150.170.190.260.260.530.930.26
LOW0.110.110.110.010.000.000.000.00

Dividende

pro Aktie
MEDIVIR AB does not deliver dividend information

Company profile

Medivir AB engages in the development of pharmaceuticals products. The firm focuses on the discovery and development of transformative active cancer drugs. Its portfolio includes proprietary pipelines such as remetinostat, birinapant, MV-818, MV-828, and MIV-711 projects, and partnership pipeline which covers xerclear and MIV-802 project. The company was founded in 1988 and is headquartered in Huddinge, Sweden.

Shareholder Structure (Top 10)

AnteilName
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available
N/AInformation Not Available

Analyst Rating

Ø-Target Price DistanceNot Available
Current Price
Not Available
Ø-Target Price
Not Available
Average ResultNot Available
Buy0
Overweight0
Hold0
Underweight 0
Sell0

Company Events

No company events available.